SKP2 My Lou, My Darling

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• MyxofibrosArcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS) are aggressive soft tissue sarcomas.
• These sarcomas exhibit high metastatic potential and resistance to conventional treatments.
• Loss of tumor suppressor genes RB1 and TP53 is common in MFS and UPS.

Purpose of the Study:

• To investigate the molecular mechanisms driving proliferation in RB1- and TP53-deficient MFS and UPS.
• To evaluate the therapeutic potential of targeting SKP2 in these sarcoma subtypes.

Main Methods:

• Analysis of RB1- and TP53-deficient MFS and UPS models.
• Assessment of SKP2 dependency for tumor cell proliferation.
• Inhibition of SKP2 using the neddylation inhibitor pevonedistat in patient-derived xenografts.

Main Results:

• Tumor growth in RB1- and TP53-deficient MFS and UPS is dependent on the oncogenic protein SKP2.
• Pevonedistat effectively inhibited SKP2 and halted tumor progression in preclinical models.
• These findings highlight SKP2 as a critical driver and potential therapeutic target.

Conclusions:

• Targeting SKP2 represents a promising therapeutic strategy for patients with RB1- and TP53-deficient MFS and UPS.
• Pevonedistat demonstrates efficacy in preclinical models, warranting further clinical investigation.